Want to see TSE:MDMA full AI Analyst Report?
MDMA Stock Chart & Stats
C$0.11
-C$0.03(-8.33%)
At close: 4:00 PM EST
C$0.11
-C$0.03(-8.33%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.20
Previous CloseN/A
Volume63.47K
Average Volume (3M)208.17K
Market Cap
C$15.79M
Enterprise ValueC$9.78
Total Cash (Recent Filing)C$564.71K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Jul 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding108,887,215
10 Day Avg. Volume94,242
30 Day Avg. Volume208,173
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt provides durable financial flexibility for a capital-intensive biotech. It reduces insolvency risk and enables the company to fund R&D, GMP capacity build or regulatory work through equity or project finance without servicing fixed interest, supporting strategic optionality as the market for MDMA therapies develops.
Sustained Revenue GrowthRecurring improvement in trailing revenue indicates growing commercial traction for pharmaceutical-grade MDMA supplies to clinical and research customers. Over 2-6 months this trend supports scaling of manufacturing utilization and the potential to spread fixed costs, a necessary step toward improving unit economics and long-term margin sustainability.
Niche Regulated Supplier Business ModelA focused model serving regulated clinical trial sponsors and research institutions creates high compliance and quality barriers to entry. Bundled services (regulatory docs, COAs, packaging) increase customer stickiness and can generate structural, recurring demand as clinical trials and potential approvals expand in the MDMA therapeutic ecosystem.
Bears Say
Negative Gross Profit And Large LossesPersistently negative gross margins and sizable operating losses undermine the path to sustainable profitability. Over months this erodes equity, limits reinvestment in production or regulatory activities, and necessitates external capital to continue operations, increasing execution risk until unit economics are corrected.
Consistent Negative Cash GenerationOngoing negative operating and free cash flow signal structural cash burn that cannot be self-funded. Reliance on external financing to cover operations increases dilution and may constrain investment in GMP capacity or compliance. Without stronger cash conversion, continuity and scaling depend on successful capital raises.
Very Small Operational HeadcountA tiny workforce creates durable operational and execution risk for a regulated biomanufacturing business. Specialized GMP manufacturing, quality assurance and regulatory interactions typically require larger internal teams; dependency on contractors or partners can slow scaling, increase costs, and raise compliance vulnerability over time.
PharmAla Biotech Holdings, Inc. News
MDMA FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was C$0.09 and its highest was C$0.20 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
PharmAla Biotech Holdings, Inc.’s market cap is C$15.79M.
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
PharmAla Biotech Holdings, Inc.’s upcoming earnings report date is Jul 24, 2026 which is today.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Overvalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 108,887,215 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in TSE:MDMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The company's offerings further extend to various MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB) and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), in addition to prepared formulations of these MDXX substances. The enterprise maintains its primary corporate offices in Vancouver, Canada.